1681.HK CONSUN PHARMA
Healthcare · Drug Manufacturers - Specialty & Generic
13.30
-0.23%
About the company
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
52-week range
Dividend deep dive
CONSUN PHARMA (1681.HK) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company currently offers a dividend yield of 5.86% in HKD, which sits below its 5-year average yield of 8.97%. The stock holds a strong overall rating of 9.0. It shows low price momentum with a score of 2.0 but indicates value with a score of 7.5.
Dividend history
The company currently has a dividend increase streak of 0 years. However, CONSUN PHARMA has demonstrated significant dividend growth, with a 3-year CAGR of 16.35% and a 5-year CAGR of 28.47%. Annual dividends per share in HKD include 0.0959 in 2014, 0.071 in 2015, 0.1411 in 2016, 0.196 in 2017, 0.20 in 2018, 0.30 in 2019, 0.18 in 2020, 0.30 in 2021, 0.40 in 2022, 0.45 in 2023, 0.90 in 2024, and 0.63 in 2025.
Dividend safety
CONSUN PHARMA's dividend is rated as 'safe'. The payout ratio stands at 54.42% of earnings. The company maintains healthy liquidity, with a current ratio of 3.219 and a quick ratio of 2.977.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 17 Aug 2026 · Information, not financial advice.
Price history
Dividend profile
Yield band A stock's current dividend yield shown against its own range over the past five years — the low, average and high. Near the high end the shares look relatively cheap for the income they pay; near the low end, relatively expensive. It's the picture behind Dividend Yield Theory. Learn more → (5-year)
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Held by 2 investors
Appears in these lists
1681.HK qualifies for these curated dividend rankings.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track 1681.HK and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →